Upfront, as always: this is for laboratory and research use only — not for human consumption. We’re discussing published pharmacology and the material we ship, not giving medical advice.
CJC-1295 is one of those compounds where the details actually matter, and the detail that trips people up most is the « No DAC » part. So before anything else, let’s clear that up — because choosing the right form is half the battle in growth-hormone-axis research.
What the research covers (and the DAC question)
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). Mechanistically it’s clean and well-described: it binds GHRH receptors on the somatotroph cells of the anterior pituitary and stimulates growth-hormone synthesis and secretion through the same pathway your body’s own GHRH uses. Published clinical-pharmacology work on the molecule reported dose-dependent rises in plasma GH and IGF-1 in healthy adult subjects.
Now, the DAC thing. The long-acting version carries a Drug Affinity Complex (DAC) that latches onto serum albumin and stretches the half-life out to roughly 8–10 days. The No-DAC form — Modified GRF (1-29) — drops that, which makes it short-acting. That’s not a downside; it’s the whole point for a lot of researchers, who specifically want a brief, pulsatile exposure rather than a slow background drip.
One accuracy note we’d rather flag than gloss over: the well-known human data (Teichman and colleagues, 2006) characterized the long-acting DAC version, while the No-DAC variant is studied as the short-acting GHRH-receptor agonist. And like the rest of this category, CJC-1295 isn’t approved by Health Canada or the FDA — it belongs in a research setting. The original Teichman paper in JCEM is the natural place to start reading.
Why researchers choose ours
GHRH-analog research is fussy about peptide identity and purity — small differences in the starting material can quietly muddy a study — so verified material is the baseline, not a bonus. Every batch of our CJC-1295 (No DAC) is independently HPLC-tested to ≥99% purity and ships with its Certificate of Analysis. It’s a 10mg lyophilized vial that dissolves cleanly, it goes out from inside Canada in sealed, insulated packaging (which, yes, matters more than people think during a humid Canadian summer), and it’s priced so a Canadian lab isn’t paying a premium or eating cross-border costs.
From researchers who’ve ordered it:
« High quality CJC-1295 with a solid COA. Arrived in 2 days to Vancouver. The 10mg vial is great value. » — Andrew S. ★★★★★
« Very happy with this product. Dissolved well and the vial seal was intact on arrival. The insulated shipping packaging was a nice touch for summer orders. » — Heather V. ★★★★
Documented purity, seals intact on arrival, clean dissolution, sensible shipping — the unglamorous fundamentals that let a GHRH-analog study start from a known quantity instead of a question mark.
The short version
CJC-1295 (No DAC) is a precise tool for growth-hormone-axis work, and precise tools deserve verified inputs. We supply research-grade CJC-1295 (No DAC) at ≥99% purity with a third-party COA, fast insulated Canadian shipping, and honest value — so the only variable in your study is the one you’re actually trying to study.
See our CJC-1295 (No DAC) 10mg and its Certificate of Analysis →
Panda Peptide supplies peptides strictly for laboratory and research use. Not for human consumption, diagnostic, or therapeutic use.